# Phase I Study of the Combination of Anlotinib With Gefitinib

> **NCT03602027** · NA · UNKNOWN · sponsor: **Second Affiliated Hospital of Nanchang University** · enrollment: 9 (estimated)

## Conditions studied

- Non-squamous Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Anlotinib
- **DRUG:** Gefitinib

## Key facts

- **NCT ID:** NCT03602027
- **Lead sponsor:** Second Affiliated Hospital of Nanchang University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-08-01
- **Primary completion:** 2018-12-01
- **Final completion:** 2019-02-01
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2018-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03602027

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03602027, "Phase I Study of the Combination of Anlotinib With Gefitinib". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03602027. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*